【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview: Immunotherapy
• Types of immunotherapy
• Key events
• Reimbursement policies
• Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
• Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of immunotherapy
• mAbs
• Immune checkpoint inhibitors
• Vaccines
• Non-specific immunotherapies
PART 09: Market segmentation by therapy area
PART 10: Geographical segmentation
• Global immunotherapy drugs market by geographical segmentation 2015-2020
• Immunotherapy drugs market in Americas
• Immunotherapy drugs market in EMEA
• Immunotherapy drugs market in APAC
PART 11: Market drivers
• Growing prevalence of cancer and autoimmune diseases
• Rise in older population
• Increase in demand for mAbs
• Patient assistance programs
• Promising pipeline
PART 12: Impact of drivers
PART 13: Market challenges
• Patent expiries of top-selling drugs
• High costs of biologicals
• Poor diagnosis and screening
• Adverse effects
• Stringent regulations
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Increase in awareness programs
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
• Expected entry of novel vaccines
PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Merck
• Amgen
• BMS
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors0
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
Exhibit 81: AbbVie: Key takeaways7
Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
Exhibit 91: Johnson & Johnson: Key takeaways3
Exhibit 92: Merck: Business segmentation by revenue 20154
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
Exhibit 100: Merck: Key takeaways2
Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
Exhibit 109: Amgen: Key takeaways9
Exhibit 110: BMS: Business segmentation by revenue 20150
Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
Exhibit 116: BMS: Key takeaways
【レポート販売概要】
■ タイトル：免疫治療薬の世界市場：モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法■ 英文：Global Immunotherapy Drugs 2016-2020
■ 発行日：2016年3月29日
■ 調査会社：Technavio
■ 商品コード：IRTNTR8772
■ 調査対象地域：世界
- 音声認識バイオメトリクス認証の世界市場2015-2019About voice recognition biometrics Biometrics helps identify individuals based on their physical or behavioral features. It involves verification and identification of physiological traits through fingerprints, face recognition, DNA, palm vein prints, hand geometry, and iris recognition, and of behavioral traits through keystroke patterns and speech pattern/voice recognition. Biometrics technologi …
- 脱毛症(Alopecia)：世界の治験レビュー（2015年上半期版）Alopecia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2015" provides an overview of Alopecia clinical trials scenario. This report provides top line data relating to the clinical trials on Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe …
- 世界のレベルセンサー市場2015The Global Level Sensors Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Level Sensors industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Level Sensors market analysis is provided for the international markets including development trends, competit …
- 世界及び中国のLEDチップ市場2015The Global and China LED Chip Industry Report 2015 is a professional and in-depth study on the current state of the LED chip industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The LED Chip market analysis is provided for the international markets including development trends, competitive landscape analys …
- 光センサーの世界市場：アンビエント照明センサー、近接センサー、RGBカラーセンサー、ジェスチャー認識、UV/IR検出The light sensors market is estimated to grow at a CAGR of 9.3% between 2016 and 2022 and is expected to reach USD 2.14 Billion by 2022. The growth of the light sensors market is driven by the growing implementation of light sensors to perform certain functions in consumer electronics such as smartphones and tablets. Also, advancements in the automotive sector, smart homes, and outdoor lighting ar …
- 化学品倉庫保管・保管の世界市場2019-2023About this market The chemical warehousing and storage industry are adopting newer and efficient warehouse and storage systems to cut down their inventory and operational costs. Operating and maintenance costs are the key expenses incurred by the chemical warehousing and storage industry. The adoption of warehouse management systems, big data and automation helps warehouses maintain and monitor th …
- カナダの末梢血管処置用機器市場見通し（～2021）Canada Peripheral Vascular Procedures Outlook to 2021 Summary GlobalData’s new report, "Canada Peripheral Vascular Procedures Outlook to 2021", provides key procedures data on the Canada Peripheral Vascular Procedures. The report provides procedure volumes within market segments - Aortic Open Repair Procedures, Aortic Stent Graft Procedures, Carotid Artery Embolic Protection Procedures, Deep Seate …
- 鎮静作用(Sedation)の治療薬パイプライン動向（2015年上半期版）Sedation - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Sedation - Pipeline Review, H1 2015’, provides an overview of the Sedation’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administr …
- バイオ燃料添加剤の世界市場2015-2022According to Stratistics MRC, the Global Biofuel Additives Market is accounted for $4,424 million in 2015 and is expected to reach $12,340 million by 2022 growing at a CAGR of 15.8% during the forecast period. Increasing biofuel usage owing to decreasing reliance on the oil producing countries and supportive government regulations are the key factors fueling the market growth. High cost of these a …
- Electric Vehicle Battery Market – Market Size, Investment Analysis, and Forecast to 2020Electric Vehicle Battery Market - Market Size, Investment Analysis, and Forecast to 2020 Summary GlobalData’s latest research “Electric Vehicle Battery Market - Market Size, Investment Analysis, and Forecast to 2020” provides insight into the market scenario related to electric vehicle batteries. The electric vehicle battery is a key component that controls the performance of the electric vehicles …
- Hugoton Royalty Trust：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Hugoton Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Hugoton Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- 民間航空機向けビデオ監視システムの世界市場Technavios market research analyst anticipates the global commercial aircraft video surveillance market to grow at a CAGR of approximately 5% by 2020. The growing emphasis on passenger safety is predicted to bolster the demand for surveillance systems during the forecast period. Moreover, the introduction of stringent policies by regulatory bodies is envisaged to necessitate the incorporation of v …
- LBC Tank Terminals：石油・ガスバリューチェーン分析レポート2013LBC Tank Terminals Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "LBC Tank Terminals" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “LBC Tank Terminals”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines t …
- 2014年戦略提言：ヨーロッパの薬物乱用検査市場Complete report $6,500. DataPack (test volumes, sales forecasts, supplier shares) $5,500.This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume …
- 再発性悪性神経膠腫(Recurrent Malignant Glioma)：世界の治験レビュー（2015年上半期版）Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the t …
